Showing 1 posts of 1 posts found.
Lonza has pushed further into the high-potency active pharmaceutical ingredient (HPAPI) sector with another round of investment at its manufacturing …
Raimond takes helm at Nuclera
Most advanced breast cancer patients treated in community settings, Phesi study finds
Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison
Bramacare opens supported-living facility for eating disorder recovery
Aiforia deal to expand access to pathology AI